Viatris Inc. (VTRS)

NASDAQ: VTRS · USD

$18.8

+0.03 (+0.2%)· Recorded snapshot

Fonte em inglêsPT

Exibindo a fonte em inglês enquanto traduzimos

Este relatório ainda não foi traduzido. Atualize em alguns minutos assim que a fila de tradução recuperar o atraso.

StockMarketAgent Research · Analyzed 2026-10-10

Our latest published analysis: VTRS rated Reduce

Viatris Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$15.9 / share

Potential value

$18.8 / share

Upside to FV

-9.8%

from $18.8

Moat

5.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$20.3B
Revenue (ttm)	14.7B
Net income (ttm)	-410.7M
EPS (ttm)	-$0.35
Shares out	1.1B
P/E (forward)	6.4x
Dividend	$0.48 (2.54%)
Volume	5,742,185
Beta	0.86

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 14.7B
Net income (ttm): -410.7M
EPS (ttm): -$0.35
P/E (forward): 6.4x
Market cap: $20.3B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$17.81B	$16.22B	$15.39B	$14.69B	$14.25B	-5.4%
Gross profit	$5.58B	$6.50B	$6.44B	$5.62B	$5.01B	-2.6%
Operating income	$-34.0M	$1.61B	$766.2M	$10.1M	$-2.66B	—
Net income	$-1.27B	$2.08B	$54.7M	$-634.2M	$-3.51B	—
EPS (diluted)	$-1.05	$1.71	$0.05	$-0.53	$-3.00	—
EBITDA	$4.48B	$6.43B	$3.52B	$2.64B	$-395.4M	—
R&D	$751.1M	$662.2M	$805.2M	$808.7M	$965.9M	+6.5%
SG&A	$4.53B	$4.18B	$4.07B	$4.10B	$3.79B	-4.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	Vender
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	Vender
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	Compra forte
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Vender
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Reduzir
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Reduzir

Base and Bull scenarios

Base55%

Price target

$15.91

-9.8% from spot

The Base case assumes Viatris executes on management guidance of ~2% operational revenue growth, achieving over 100 new product approvals while maintaining operating margins around 16.5% to 18.5%. Operating cash flow of approximately $2.3B supports ongoing debt reduction, yielding a Fair value of $15.91.

Consolidated revenue growth moderates over the projection period following modest expansion in FY2026
Normalized operating margin expands steadily over the forecast period
Terminal P/E multiple expands modestly toward peer baseline levels
Annual free cash flow supports sustained debt paydown and modest share count contraction

Bull20%

Price target

$18.81

+6.6% from spot

The Bull case envisions accelerated commercialization of complex generics and specialty pipeline assets, such as meloxicam reaching peak sales potential up to $500M. Operating margins expand substantially and rapid deleveraging drives multiple re-rating toward peer levels.

Operating margins expand substantially driven by complex generics and proprietary specialty assets
Meloxicam reaches peak sales potential up to $500M with multi-year exclusivity
Terminal multiple expands toward peer levels like Baxter's 11.94x forward P/E
EPS compounding accelerates substantially above baseline rates annually

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($15.91). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	1.8%	2.0%	2.3%	2.5%
8.1%	$16.5	$16.5	$16.5	$16.5	$16.5
8.6%	$16.2	$16.2	$16.2	$16.2	$16.2
9.1%	$15.9	$15.9	$15.9	$15.9	$15.9
9.6%	$15.6	$15.6	$15.6	$15.6	$15.6
10.1%	$15.3	$15.3	$15.3	$15.3	$15.3

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E6.4

P25 n/aP50 n/aP75 n/a

Trailing P/E0

P25 n/aP50 n/aP75 n/a

ROE-2.8

P25 n/aP50 n/aP75 n/a

ROIC5.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VTRS indicators

Market & fundamental data

Available fields

266

Groups with data

Currency

USD

Showing 266 of 266 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001792044
Company name	Viatris Inc.
Country	United States
Country code	US
CUSIP number	92556V106
Earnings date	2026-11-05
Earnings time	bmo
Employees	30,000
Employees change	-2,000
Employees growth	-6.25%
Enterprise value	$33.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1961
In index	SP500
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US92556V1061
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2003-10-09
Last stock split type	Forward
Market cap	$21.5B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$18.75
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	VTRS
U.S. state	Pennsylvania
Website	https://www.viatris.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	7.44x
Average P/E ratio (10Y)	84.86x
Earnings yield	-1.89%
EV/EBIT	21.49x
EV/EBITDA	7.85x
EV/FCF	17.24x
EV/Sales	2.29x
FCF / EV yield	5.8%
FCF yield	9.06%
Forward EV/Sales	2.26x
Forward P/E	7.37x
Forward P/S	1.45x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	12.11x
P/(OCF - SBC) ratio	10x
P/B ratio	1.52x
P/FCF ratio	11.04x
P/OCF ratio	9.26x
P/S ratio	1.46x
PEG ratio	2.52x
Price/EBITDA ratio	5.03x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	10.64%
EBITDA margin	29.13%
FCF margin	13.26%
Gross margin	40.31%
Operating margin	10.64%
Pretax margin	-4.49%
Profit margin	-2.79%
Profit per employee	$-13,690
Revenue per employee	$491,243
ROA	2.67%
ROA (5Y)	2.25%
ROCE	5.46%
ROE	-2.75%
ROE (5Y)	-3.98%
ROIC	5.89%
ROIC (5Y)	3.5%
SBC / revenue	1.17%
Tax / revenue	-1.71%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth	11.61%
FCF growth (Q)	97.24%
FCF growth (QoQ)	-5.57%
FCF growth 3Y	-2.89%
FCF growth 5Y	3.13%
Gross profit growth	3.13%
Gross profit growth (Q)	9.93%
Gross profit growth 3Y	-4.17%
Gross profit growth 5Y	-1.04%
Net income growth years	0
OCF growth	12.9%
OCF growth (Q)	73.78%
OCF growth (QoQ)	-1.67%
OCF growth 10Y	0.93%
OCF growth 3Y	-2.41%
OCF growth 5Y	3.43%
Operating income growth	22.89%
Operating income growth (Q)	38.27%
Operating income growth 3Y	-12.23%
Operating income growth 5Y	4.24%
Revenue growth	4.4%
Revenue growth (Q)	4.88%
Revenue growth (QoQ)	6.82%
Revenue growth 10Y	4.02%
Revenue growth 3Y	-1.88%
Revenue growth 5Y	-1.14%
Revenue growth quarters	4
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-376M
Depreciation and amortization	$2.7B
EBIT	$1.6B
EBITDA	$4.3B
EPS	$-0.35
FCF per share	$1.70
Financing cash flow	$-1.9B
Free cash flow	$2B
Free cash flow minus SBC	$1.8B
Gross profit	$5.9B
Income taxes	$-251.5M
Investing cash flow	$-84.3M
Net borrowing	$-923.5M
Net cash flow	$322.2M
Net income	$-410.7M
Operating cash flow minus SBC	$2.2B
Operating income	$1.6B
Revenue	$14.7B
Stock-based compensation	$172.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.1
Book value per share	$12.34
Debt / EBITDA	3.11
Debt / equity	0.96
Debt / FCF	6.97
Goodwill	$6.7B
Interest coverage	3.27
Long-term assets	$25B
Long-term liabilities	$14.4B
Net cash (debt)	$-12.1B
Net cash / market cap	-56.13%
Net debt / EBITDA	2.82
Net debt / equity	0.85
Net debt / FCF	6.2
Piotroski F-Score	6
Property, plant and equipment	$2.7B
Shareholders' equity	$14.3B
Tangible book value	$-6.1B
Tangible book value per share	$-5.26
Total assets	$35B
Total cash	$1.5B
Total debt	$13.6B
Total liabilities	$20.8B
WACC	6.57%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.4
Current assets	$10.1B
Current liabilities	$6.3B
Current ratio	1.58
Inventory turnover	2.15
Net working capital	$4.1B
Quick ratio	0.82
Working capital	$3.7B
Working capital turnover	4.64

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.45%
Dividend growth	0%
Dividend growth (10Y)	15.87%
Dividend growth (3Y)	0%
Dividend growth (5Y)	16.89%
Dividend growth years	0
Dividend payment date	2026-09-16
Dividend payment years	6
Dividend payout frequency	Quarterly
Dividend per share	$0.48
Dividend yield	2.54%
Ex-dividend date	2026-08-21
FCF payout ratio	28.2%
Last dividend	$0.12
Shareholder yield	5%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-50.47%
10Y return CAGR	-4.67%
10Y total return	-37.98%
150-day SMA	$16.36
15Y price change	-7.47%
15Y return CAGR	0.99%
15Y total return	15.87%
1D price change	0.16%
1M price change	5.61%
1M total return	5.61%
1W price change	0.97%
1W total return	0.97%
1Y price change	80.71%
1Y return CAGR	87.2%
1Y total return	87.12%
20-day SMA	$17.98
200-day SMA	$15.84
20Y price change	-10.76%
20Y return CAGR	0.6%
20Y total return	12.77%
3M price change	6.78%
3M total return	7.58%
3Y price change	114.71%
3Y return CAGR	34.53%
3Y total return	143.55%
50-day SMA	$17.34
50-day SMA vs 200-day SMA	50over200
52-week high	$18.93
52-week high date	2026-10-28
52-week low	$9.92
52-week low date	2025-11-07
5Y price change	43.74%
5Y return CAGR	12.15%
5Y total return	77.39%
6M price change	27.14%
6M total return	29.04%
All-time high	$76.69
All-time high date	2015-04-24
All-time low	$0.60
All-time low date	1984-05-16
Average true range (ATR)	$0.48
Average volume	8.3M
Beta (1Y)	0.44
Beta (2Y)	0.92
Beta (5Y)	0.86
Change from 52-week high	-0.95%
Change from 52-week low	89.01%
Change from all-time high	-75.45%
Change from all-time low	3,012.91%
Change from open	1.13%
Day's gap	-0.96%
Dollar volume	$107.7M
High price	$18.92
Low price	$18.51
Monthly RSI	69.99
Open price	$18.54
Position in 52-week range	58.54%
Premarket change	-0.11%
Premarket close	$18.72
Premarket price	$18.70
Premarket volume	1.2K
Previous close	$18.72
Price vs 150-day SMA	15.08%
Price vs 20-day SMA	4.73%
Price vs 200-day SMA	18.9%
Price vs 50-day SMA	8.62%
Relative volume	0.69
RSI	63.47
Sharpe ratio	1.97
Sharpe ratio (3Y)	0.94
Sharpe ratio (5Y)	0.35
Sortino ratio	3.52
Sortino ratio (3Y)	1.6
Sortino ratio (5Y)	0.67
Volume	5.7M
Weekly RSI	67.1
YTD price change	51.25%
YTD total return	54.81%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.1B
Float percentage	99.41%
Shares change (QoQ)	-1.02%
Shares change (YoY)	-2.45%
Shares held by insiders	0.43%
Shares held by institutions	96.11%
Shares outstanding	1.1B
Short % of float	3.68%
Short % of shares	3.66%
Short ratio	4.7 days

Deeper analysis on VTRS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this VTRS report

What is the latest published VTRS stock rating?

Viatris Inc. is shown with Reduce in the latest published report, analyzed 2026-10-10. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VTRS analysis?

The full latest published report, analyzed 2026-10-10, lives at /stocks/VTRS/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for VTRS?

The latest published report analyzed 2026-10-10 gives VTRS a fair value of USD 16 and a potential value of USD 19. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the VTRS page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-10). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ReduceVTRS · Fair value $15.9-9.8%

Read full analysis →

Viatris Inc. (VTRS)

Our latest published analysis: VTRS rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · VTRS

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All VTRS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VTRS

Frequently asked questions

Histórico de classificações

Category	Score	Reading
Valuation	3.0
Management	7.5
Balance Sheet	6.0
Profitability	1.5
Revenue Growth	4.5
Risk Assessment	6.5
Competitive Moat	5.5
Earnings Quality	3.0
Capital Efficiency	2.5